By Ana Espino | Published on January 8, 2026 | 3 min readAlcohol and drug dependence
represent a major public health issue and are frequently observed as comorbid
conditions. When a substance use disorder (SUD) co-occurs with problematic
alcohol consumption, clinical outcomes are more severe:
increased risk of
relapse,
worsening of psychiatric disorders, and
reduced response to treatment.
One of the
main limitations of current approaches is that they too often
consider each addiction separately, without integrating the biological,
neurocognitive, and behavioral interactions between substances.
The
central challenge is therefore
to
better understand the shared neurobiological mechanisms involved in this
dual dependence, in order to develop integrated and
more effective therapeutic
strategies. In this context, the aim of this review is to synthesize current
knowledge on
alcohol–drug comorbidity by analyzing the neural pathways
involved, cross-substance effects, and their clinical implications for patient
management.
Double addiction, double impact?
This narrative review is based on an
analysis of
experimental and clinical data from the scientific literature. The
authors selected studies examining the combined impact of alcohol and other
addictive substances—particularly
opioids, cocaine, methamphetamine, cannabis,
and
nicotine—to describe
shared neurobiological mechanisms, pharmacodynamic
interactions, and the clinical implications of this comorbidity.
The findings highlight a deleterious
synergy between alcohol and drugs, primarily driven by
activation of the
mesolimbic dopaminergic system involved in reward circuitry. This dual
activation reinforces substance-seeking behaviors while weakening inhibitory
control mechanisms. Alcohol tends to potentiate the psychoactive effects of
other drugs, thereby promoting cross-tolerance, increased craving, and
escalation of consumption.
Clinically, patients with combined
dependence show a
higher risk of relapse, reduced therapeutic efficacy, and a
high prevalence of psychiatric comorbidities such as anxiety, depression, and
mood disorders. Data from animal models support these observations, showing
hypersensitization of reward circuits and progressive desensitization of
behavioral regulation mechanisms. These cross-effects significantly complicate
clinical management and call for specific therapeutic approaches.
One brain, two addictions, one
strategy to rethink
Comorbidity between
alcohol
dependence and drug use constitutes a particularly complex clinical profile,
associated with symptom exacerbation, diminished treatment response, and
increased relapse risk. One of the main challenges is to
understand the neurobiological
mechanisms underlying this dual dependence in order to propose integrated care
tailored to patients who often fail standard treatments. This review aimed to
synthesize current data on interactions between alcohol and addictive
substances, emphasizing their synergistic effects on reward and control
circuits. It confirms that this association worsens clinical severity and
strengthens addictive behaviors.
However, limitations of this study
remain and justify further research. Most available data are based on animal
models or uncontrolled clinical observations, with few randomized trials
specifically dedicated to dual dependence. Future research should include
longitudinal studies in real-world populations,
targeted therapeutic
strategies, and
more precise stratification tools to identify the most
vulnerable profiles. It will also be necessary to e
valuate the effectiveness of
combined treatment approaches and to integrate innovative methods—such as
neuroimaging and personalized medicine—to better understand and treat the
complex mechanisms underlying this dual dependence.
Read next: Tobacco: a deeper addiction than it seems
About the author – Ana EspinoPhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.